36 results
8-K
EX-99.1
HOWL
Werewolf Therapeutics Inc
3 May 24
Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
7:05am
fixed payments received from Jazz, plus costs incurred for research services to be reimbursed by Jazz.
Research and development expenses: Research … in research and development expenses was primarily due to the Company’s development efforts for WTX-124 and WTX-330, which continue to progress through
8-K
EX-99.1
HOWL
Werewolf Therapeutics Inc
7 Mar 24
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
7:11am
and development expenses: Research and development expenses were $9.6 million for the fourth quarter of 2023, compared to $15.9 million for the same … period in 2022. Research and development expenses were $41.8 million for the full year 2023, compared to $53.8 million for the full year 2022.
General
424B5
rvp3zr0a91xb
9 Feb 24
Prospectus supplement for primary offering
4:35pm
8-K
EX-99.1
pjzc6bidn2 st
14 Nov 23
Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
4:34pm
8-K
EX-99.1
kbuwbg
10 Aug 23
Werewolf Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
7:16am
8-K
EX-99.1
k6kigp
11 May 23
Werewolf Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
7:05am
8-K
EX-99.1
xn2iv2fzoh4mkadvs3n
10 Nov 22
Werewolf Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
7:05am
8-K
EX-99.1
mbrjnvf4n2tpb86yjyp
11 Aug 22
Werewolf Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Highlights
7:02am
S-3
6p9u148 vqz0rm5qp
10 May 22
Shelf registration
5:02pm